A novel inducible expression system to study transdominant mutants of HIV-1 Vpr

被引:21
作者
Zhou, Y
Ratner, L
机构
[1] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA
关键词
Vpr; HIV-1; transdominant; G2 cell cycle arrest; ecdysone; episomal vector;
D O I
10.1006/viro.2001.1031
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In this study, an episomal system for ecdysone-inducible gene expression was developed. Human embryonic kidney 293 cells (293VE) expressing a heterodimer of modified ecdysone and retinoid X receptors and the Epstein-Barr nuclear antigen-1 were screened. Plasmids containing the EBV replication origin, oriP and the ecdysone-response element could replicate and persist in 293VE cells to inducibly express luciferase or Vpr. The induction level, tested with luciferase reporter plasmid, varied among cell lines from 254- to 2056-fold. In one highly inducible cell line, HIV-1 Vpr was expressed well and caused G2 cell cycle arrest in the presence of the inducer, while in the absence of the inducer, no Vpr protein or cell cycle arrest could be detected. Using different selection markers, HIV-1 Vpr was coexpressed with Vpr mutants defective in phosphorylation at Ser79 and G2 cell cycle arrest activity. These Vpr mutants were transdominant to wild-type Vpr for G2 cell cycle arrest activity, but did not alter wild-type Vpr phosphorylation. It is likely that the transdominant mutants and wild-type Vpr compete for a downstream target(s) of G2 cell cycle arrest. (C) 2001 Academic Press.
引用
收藏
页码:133 / 142
页数:10
相关论文
共 44 条
[1]   The HIV-1 Vpr co-activator induces a conformational change in TFIIB [J].
Agostini, I ;
Navarro, JM ;
Bouhamdan, M ;
Willetts, K ;
Rey, F ;
Spire, B ;
Vigne, R ;
Pomerantz, R ;
Sire, J .
FEBS LETTERS, 1999, 450 (03) :235-239
[2]   The human immunodeficiency virus type 1 Vpr transactivator: Cooperation with promoter-bound activator domains and binding to TFIIB [J].
Agostini, I ;
Navarro, JM ;
Rey, F ;
Bouhamdan, M ;
Spire, B ;
Vigne, R ;
Sire, J .
JOURNAL OF MOLECULAR BIOLOGY, 1996, 261 (05) :599-606
[3]  
Ausubel FA, 1995, CURRENT PROTOCOLS MO
[4]   HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B [J].
Ayyavoo, V ;
Mahboubi, A ;
Mahalingam, S ;
Ramalingam, R ;
Kudchodkar, S ;
Williams, WV ;
Green, DR ;
Weiner, DB .
NATURE MEDICINE, 1997, 3 (10) :1117-1123
[5]   HUMAN-IMMUNODEFICIENCY-VIRUS VPR PRODUCT IS A VIRION-ASSOCIATED REGULATORY PROTEIN [J].
COHEN, EA ;
DEHNI, G ;
SODROSKI, JG ;
HASELTINE, WA .
JOURNAL OF VIROLOGY, 1990, 64 (06) :3097-3099
[6]   The HIV-1 vpr protein acts as a negative regulator of apoptosis in a human lymphoblastoid T cell line: Possible implications for the pathogenesis of AIDS [J].
Conti, L ;
Rainaldi, G ;
Matarrese, P ;
Varano, B ;
Rivabene, R ;
Columba, S ;
Sato, A ;
Belardelli, E ;
Malorni, W ;
Gessani, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (03) :403-413
[7]   FUNCTIONS OF THE AUXILIARY GENE-PRODUCTS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
CULLEN, BR ;
GREENE, WC .
VIROLOGY, 1990, 178 (01) :1-5
[8]   MUTATIONAL ANALYSIS OF CELL-CYCLE ARREST, NUCLEAR-LOCALIZATION, AND VIRION PACKAGING OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VPR [J].
DIMARZIO, P ;
CHOE, S ;
EBRIGHT, M ;
KNOBLAUCH, R ;
LANDAU, NR .
JOURNAL OF VIROLOGY, 1995, 69 (12) :7909-7916
[9]   HIV transcriptional activation by the accessory protein, VPR, is mediated by the p300 co-activator [J].
Felzien, LK ;
Woffendin, C ;
Hottiger, MO ;
Subbramanian, RA ;
Cohen, EA ;
Nabel, GJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (09) :5281-5286
[10]   The HIV-1 Vpr displays strong anti-apoptotic activity [J].
Fukumori, T ;
Akari, H ;
Iida, S ;
Hata, S ;
Kagawa, S ;
Aida, Y ;
Koyama, AH ;
Adachi, A .
FEBS LETTERS, 1998, 432 (1-2) :17-20